Significance of Technology for Parkinson’s Disease

Human intelligence alone is not enough to find a cure for Parkinson’s…

Without the right technology, how do you know which patients may best respond to specific therapies?…

How do you diagnose patients earlier so that you can test medicines before massive damage?

We knew a technological approach could calculate insights beyond what we were able to do on the whiteboard – and could build hypotheses based on human patient data.

Animal models offer some insights, but ultimately we need to focus on patients to find the answers.

That is why we created a technology that would take the profiles of patients,

Create a simulated patient brain cell to test these hypothetical therapeutics.

New technologies help us to:

#1. Enable earlier disease detection so interventions can slow or stop progression before symptoms start.

#2. Enhance tailoring of human trials mapping the right drug for the right set of patients.

#3. Improve the way clinical trials are designed with quantitative biomarkers and clear recruitment criteria.

Once we find gaps that can be solved with better technology to make sense of these massive amounts of data,

We build new reusable tools that solve these gaps across any disease, gene, or target.

Today, we have a suite of tools that can solve a wide array of drug development challenges,

analyze complex biological systems, find the optimal targets for intervention, and find initial chemicals that can modulate these targets.

Our technologies also help us make sense of which patients are ideal for a particular trial.

And as we progress, we find that there’s always a next gap that can be solved using technology.

With massive amounts of research data coming out and rapid advances in AI technologies, we have the tools that drive insights and innovations that weren’t possible just a few years ago.

These tools have been fruitful, yielding small molecule drug programs running in parallel, which have come out of this platform with a shockingly efficient process poised to grow in several new directions.

We’re just getting started and gaining attention from pharmaceutical partners looking for new assets and new ways to optimize drug development workflows.

If you want to learn more about us and what we are doing to conquer age-related diseases.

← You can read more at vincerebio{com}.

Read the post on Linkedin: Click here